• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Indian Journal of Hematology Blood Transfusion >Infusion Related Hypersensitivity Reactions with Bio-similar Anti CD-20 Monoclonal Antibody Rituximab in Indian Patients: A Retrospective Study
【2h】

Infusion Related Hypersensitivity Reactions with Bio-similar Anti CD-20 Monoclonal Antibody Rituximab in Indian Patients: A Retrospective Study

机译：生物类似抗CD-20单克隆抗体利妥昔单抗在印度患者中的输液相关超敏反应：一项回顾性研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

There is paucity of data on infusion related hypersensitivity reactions (IRHR) pattern of bio-similar rituximab in B-cell lymphoma patients. As bio-similar molecules are independently developed monoclonal antibodies, they are likely to differ in immunogenicity and therefore, the hypersensitivity data of the innovator rituximab may not be directly applicable to patients treated with the biosimilar rituximab molecule. We analysed our data of 256 patients of B cell lymphoid neoplasm who received bio-similar rituximab (Reditux) based chemo-immunotherapy for their treatment. Total 56/256 (21.8%) patients had ≥ grade II IRHR with first dose of rituximab. Grade II reactions were seen in 32/256 (12.5%) cases, grade III and grade IV reactions were seen in 21/256 (8.2%) and 3/256 (1.2%) cases, respectively. Rituximab was withdrawn from all further therapy in only 2 patients due to grade IV IRHR after attempting re-challenge of the drug under intensive monitoring. There was no difference in complete response rates in patients with or without IRHR during their first rituximab infusion. The IRHRs with bio-similar rituximab noted in our study were comparable with the previously published reactions associated with the original rituximab.
机译：B细胞淋巴瘤患者中生物相似的利妥昔单抗的输注相关超敏反应（IRHR）模式的数据很少。由于生物相似分子是独立开发的单克隆抗体，因此它们的免疫原性可能会有所不同，因此，创新者利妥昔单抗的超敏数据可能不适用于使用生物相似利妥昔单抗分子治疗的患者。我们分析了256例接受基于生物相似的利妥昔单抗（Reditux）的化学免疫疗法治疗的B细胞淋巴瘤患者的数据。总共56/256（21.8％）的患者接受初次利妥昔单抗的II级IRHR≥。 II级反应发生在32/256（12.5％）情况下，III级和IV级反应发生在21/256（8.2％）和3/256（1.2％）情况下。利妥昔单抗仅在2名患者中因IV级IRHR而退出所有进一步治疗，之后在强化监护下尝试再次挑战该药物。有或无IRHR的首次利妥昔单抗输注患者的完全缓解率无差异。我们研究中提到的具有生物相似的利妥昔单抗的IRHR与先前发表的与原始利妥昔单抗相关的反应相当。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号